混合肿瘤未正式列入最新的国际肾脏肿瘤组织学分类(WHO,2022),然而,根据文献,许多研究人员仍然认为杂种肿瘤是一个独立的病理学单位.在这方面,杂种肿瘤的形态学和分子遗传学标准的发展,今天,是嗜酸细胞肾肿瘤鉴别诊断的主要任务。
目的:我们的目的是进行免疫组织化学鉴定,超微结构特征,并确定混合肾肿瘤的分子谱。
方法:这项研究是对12例肾脏杂合瘤患者的手术材料进行的。根据标准方案在石蜡切片上进行免疫组织化学研究。抗体CK7,CD117,细胞周期蛋白D1,EpCAM,Caveolin1,EABA,使用S100A1。为了研究半薄和超薄切片上的肿瘤组织,使用电子显微镜PhilipsTECNAI12BioTwinD-265。对于原位荧光诊断检测,确定的着丝粒探针,LSI13/21、LSIN25/LSIARSA和TelVysion端粒探针。
结果:在某些情况下,杂种肿瘤由具有特征性免疫的单形亲氧细胞的实体结构表示,超表型和分子谱。
结论:综合研究结果证实,杂合瘤是嗜酸细胞瘤向肾嫌色细胞癌恶性转化过程中的中间环节。
A hybrid tumor is not officially included in the latest International Histological Classification of Kidney Tumors (WHO, 2022), however, according to the literature, a number of researchers still consider a hybrid tumor as an independent nosological unit. In this regard, the development of morphological and molecular genetic criteria for a hybrid tumor, today, is the main task in the differential diagnosis of oncocytic renal tumors.
OBJECTIVE: Our aim was to carry out to identify immunohistochemical, ultrastructural features and determine the molecular profile of hybrid renal tumors.
METHODS: The study was performed on the surgical material of 12 patients with a hybrid tumor of the kidney. Immunohistochemical study was carried out on paraffin sections according to the standard protocol. Antibodies CK7, CD117, Cyclin D1, EpCAM, Caveolin1, EABA, and S100A1 were used. To study tumor tissues on semi-thin and ultra-thin sections, an electron microscope Philips TECNAI 12 BioTwinD-265 is used. For in situ fluorescent diagnostic detection, defined centromere probes, LSI 13/21, LSI N25 /LSI ARSA and TelVysion telomeric probe.
RESULTS: In some cases, a hybrid tumor is represented by a solid structure of monomorphic oxyphilic cells with a characteristic immuno-, ultraphenotype and molecular profile.
CONCLUSIONS: The results of a comprehensive study confirm that the hybrid tumor is an intermediate link in the process of malignant transformation of oncocytoma into chromophobe renal cell carcinoma.